Frequent exacerbations in COPD are associated with accelerated rate of FEV1 decline Source: Eur Respir J 2006; 28: Suppl. 50, 32s Year: 2006
The evaluation of different factors that cause FEV1 decline in patients with COPD Source: Eur Respir J 2001; 18: Suppl. 33, 135s Year: 2001
Biomarkers to predict FEV1 decline in smokers and early-onset COPD. Source: Virtual Congress 2020 – Intercellular communication in tissue remodelling of chronic lung diseases Year: 2020
Polymorphisms in surfactant proteins and FEV1 decline and development of COPD in the general population Source: Eur Respir J 2006; 28: Suppl. 50, 143s Year: 2006
Intermediate and severe α1 -antitrypsin deficiency: influence on plasma α1 -antitrypsin, FEV1 and risk of COPD. Three meta-anlyses Source: Eur Respir J 2002; 20: Suppl. 38, 513s Year: 2002
Frequent exacerbations in ex smokers with COPD are associated with accelerated rate of FEV1 decline Source: Eur Respir J 2005; 26: Suppl. 49, 510s Year: 2005
Which markers other than FEV1 reflect disease progression in COPD? Source: Eur Respir J 2004; 24: Suppl. 48, 45s Year: 2004
Increasing risk of exacerbation and mortality associated with increasing frequency and severity of exacerbations in COPD patients: EXACOS-UK Source: Virtual Congress 2021 – Prediction of exacerbations in patients with COPD Year: 2021
Predictors of accelerated decline in lung function in adult-onset asthma Source: Eur Respir J, 51 (2) 1701785; 10.1183/13993003.01785-2017 Year: 2018
A polymorphism in DNASE1L3 is associated with severe asthma exacerbations in two-high risk populations for asthma Source: International Congress 2019 – Understanding, monitoring and targeting severe asthma Year: 2019
The role of concomitant respiratory diseases on the rate of decline in FEV1 among adult asthmatics Source: Eur Respir J 2003; 21: 95-10 Year: 2003
The median number of COPD exacerbations per year in patients with different polymorphisms of the gene ADRB2 Source: International Congress 2015 – Notable abstracts in exacerbations, mechanisms and biomarkers in COPD Year: 2015
Both moderate and severe exacerbations accelerate physical activity decline in COPD patients Source: Eur Respir J, 51 (1) 1702110; 10.1183/13993003.02110-2017 Year: 2018
Prevalence of alpha1-antitrypsin deficiency and its influence on lung function decline in patients with severe asthma Source: Virtual Congress 2020 – Advances in asthma treatment Year: 2020
Individual decline of FEV1 show diversity in COPD Source: Annual Congress 2012 - Environmental exposure and other risk factors for airway diseases Year: 2012
Exacerbations and duration of smoking abstinence are associated with the annual decline in lung function in individuals with PiZZ alpha-1-antitrypsin deficiency Source: International Congress 2017 – Current challenges in COPD evaluation Year: 2017
FVC decline over 1 year predicts mortality but not subsequent FVC decline in patients with IPF Source: International Congress 2017 – Idiopathic pulmonary fibrosis: from the bench to the bedside Year: 2017
Cardiac disease from accelerated FEV1 decline and acute exacerbations: time to rethink comorbidities in COPD Source: Eur Respir J, 57 (3) 2004008; 10.1183/13993003.04008-2020 Year: 2021
Predictors for the rapid decline of FEV1 in chronic obstructive lung disease Source: Eur Respir J 2002; 20: Suppl. 38, 255s Year: 2002
Polymorphisms in 17q12-21 are associated with asthma exacerbation and lung function in asthmatic children Source: Annual Congress 2011 - Inflammation and genes in childhood asthma Year: 2011